Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Driven by 2 papers. Top paper: “FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer”.
Tatiana M. Prowell, Jennifer Gao, Laura L. Fernandes, Emily Li, Xiling Jiang +29 more
Maxwell Korang‐Yeboah, David D. Anderson, John Arigo, Thomas O’Connor, Rakhi B. Shah +1 more